Looking for a reason to consider adding exposure to the China healthcare sector to your portfolio?
Now may actually be a very good time to do so. Earlier in September, the South China Morning Post reported that China’s healthcare sector has seen about $10.6 billion in fundraising this year, according to Dealogic. Crucially, 2025’s fundraising numbers are higher than the combined fundraising totals from the years 2022, 2023, and 2024 put together.
The article highlighted a few particular names in the China healthcare scene who are leading the way in fundraising. WuxiAppTec raised around $980 million from a Hong Kong share placement, according to the South China Morning Post. Meanwhile, the article notes that Hansoh Pharmaceutical Group recently accrued $500 million through a new shares issue.
Fundraising has been flowing into the sector through IPOs as well. As the article notes, Jiangsu Pharmaceuticals pulled in about $1.3 billion through its Hong Kong listing back in May.
With record money flowing into this sector, advisors and investors alike might want to consider bolstering their exposure to these leading China healthcare companies. Not only can these companies offer crucial diversification, but they may be in pole position to offer compelling long-term growth as well.
KURE Offers Exposure to China's Healthcare Giants
For those looking to add more China healthcare companies to their portfolio, KraneShares can help. Situations like these are exactly what the KraneShares MSCI All China Health Care Index ETF (KURE ) was built for.
Within the cost-efficient ETF wrapper, KURE provides easy and direct access to many of China’s leading healthcare companies. As a matter of fact, WuXi AppTec, Hansoh Pharmaceutical Group, and Jiangsu Pharmaceuticals are all some of the top holdings within the fund’s portfolio.
This puts KURE in an especially good position to ride out the momentum in China healthcare fundraising. With many of the fund’s top holdings pulling in strong fundraising numbers, the fund remains in a good position to deliver compelling returns in both the short and long term.
So far, KURE has managed to put up an extremely strong performance this year, despite the threat of tariffs. Year-to-date, the fund’s NAV is up 41.47%, as of August 31, 2025.
For more news, information, and analysis, visit the China Insights Content Hub.
